HomeCompareICVX vs PM

ICVX vs PM: Dividend Comparison 2026

ICVX yields 13.06% · PM yields 3.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PM wins by $2.4K in total portfolio value· pulled ahead in Year 9
10 years
ICVX
ICVX
● Live price
13.06%
Share price
$15.31
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.3K
Annual income
$2,943.04
Full ICVX calculator →
PM
Philip Morris International
● Live price
3.49%
Share price
$164.83
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,502.61
Full PM calculator →

Portfolio growth — ICVX vs PM

📍 PM pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodICVXPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ICVX + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ICVX pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ICVX
Annual income on $10K today (after 15% tax)
$1,110.39/yr
After 10yr DRIP, annual income (after tax)
$2,501.58/yr
PM
Annual income on $10K today (after 15% tax)
$297.03/yr
After 10yr DRIP, annual income (after tax)
$2,127.22/yr
At 15% tax rate, ICVX beats the other by $374.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ICVX + PM for your $10,000?

ICVX: 50%PM: 50%
100% PM50/50100% ICVX
Portfolio after 10yr
$48.5K
Annual income
$2,722.83/yr
Blended yield
5.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

ICVX
Analyst Ratings
5
Buy
1
Hold
Consensus: Buy
Price Target
$27.00
+76.4% upside vs current
Range: $27.00 — $27.00
Altman Z
22.6
Piotroski
3/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.9% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ICVX buys
0
PM buys
0
No recent congressional trades found for ICVX or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricICVXPM
Forward yield13.06%3.49%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$47.3K$49.6K
Annual income after 10y$2,943.04$2,502.61
Total dividends collected$21.0K$11.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$27.00$194.30

Year-by-year: ICVX vs PM ($10,000, DRIP)

YearICVX PortfolioICVX Income/yrPM PortfolioPM Income/yrGap
1$12,006$1,306.34$11,650$409.56+$356.00ICVX
2$14,313$1,465.82$13,592$497.49+$721.00ICVX
3$16,948$1,633.07$15,882$605.21+$1.1KICVX
4$19,941$1,807.22$18,589$737.41+$1.4KICVX
5$23,324$1,987.33$21,794$899.94+$1.5KICVX
6$27,129$2,172.42$25,597$1,100.16+$1.5KICVX
7$31,390$2,361.53$30,118$1,347.30+$1.3KICVX
8$36,141$2,553.64$35,505$1,652.97+$636.00ICVX
9← crossover$41,419$2,747.79$41,940$2,031.88$521.00PM
10$47,261$2,943.04$49,643$2,502.61$2.4KPM

ICVX vs PM: Complete Analysis 2026

ICVXStock

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.

Full ICVX Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this ICVX vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ICVX vs SCHDICVX vs JEPIICVX vs OICVX vs KOICVX vs MAINICVX vs MOICVX vs BTIICVX vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.